, Tracking Stock Market Picks
Enter Symbol:
BioLineRx, Ltd. (BLRX) [hlAlert]

down 26.88 %

BioLineRx, Ltd. (BLRX) rated Buy with price target $4 by Maxim Group

Posted on: Monday,  Aug 17, 2015  4:25 PM ET by Maxim Group

Maxim Group rated Buy BioLineRx, Ltd. (NASDAQ: BLRX) on 08/17/2015. Previously Maxim Group rated Buy BioLineRx, Ltd. (NASDAQ: BLRX) on 12/16/2014.,
when the stock price was $1.86. Since then, BioLineRx, Ltd. has lost 26.88% as of 09/24/2015's recent price of $1.36.
If you would have followed the previous Maxim Group's recommendation on BLRX, you would have lost 26.88% of your investment in 282 days.

BioLineRx, Ltd. operates as a clinical-stage biopharmaceutical development company worldwide. Its clinical therapeutic candidates under development include BL-1020, a Phase IIb completed product for the treatment of schizophrenia; BL-1040, a Phase I/II clinical trial completed medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients; and BL-5010, a novel formulation under Phase I/II clinical trial for non surgical removal of skin lesions. The company?s product pipeline under pre-clinical stage of development includes BL-1021 for neuropathic pain; BL-2030 for autoimmune diseases; BL-4010 for cancer tumors; BL-4040 for acute kidney failure; BL-5030 for thromboembolic diseases; BL-5040 for inflammatory diseases and pathological weight loss; BL-6010 for type II diabetes; BL-6020 for cancer cachexia; and BL-6030 for bacterial biofilm. It also operates a biotechnology incubator to evaluate and develop pre-clinical therapeutic candidates. The company was founded in 2003 and is based in Jerusalem, Israel.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/17/2015 4:25 PM Buy
1.59 4.00
as of 8/27/2015
1 Week down  -2.85 %
1 Month down  -41.12 %
3 Months down  -30.25 %
1 YTD down  -14.46 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/16/2014 8:25 AM Buy
1.86 8.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy